陳 明堯

Medicine & Life Sciences

1. Sorafenib 100%
2. antrocin 94%
3. Hepatocellular Carcinoma 86%
4. ravidasvir 81%
5. Ribavirin 78%
6. ovatodiolide 73%
7. antroquinonol 72%
8. danoprevir 68%
9. Glucose Transporter Type 2 61%
10. Colorectal Neoplasms 55%
11. Phloretin 53%
12. Genotype 49%
13. Hydroxychloroquine 46%
14. 4-acetylantroquinonol B 46%
15. Neoplasms 45%
16. Beclin-1 44%
17. Ritonavir 44%
18. Alcoholic Liver Diseases 43%
19. Cetuximab 43%
20. Plasmacytoma 43%
21. Upper Gastrointestinal Tract 42%
22. Retreatment 42%
23. Autophagy 39%
24. Polyphenols 38%
25. Interleukins 38%
26. Long Noncoding RNA 37%
27. Propensity Score 37%
28. Genetic Polymorphisms 36%
29. Foreign Bodies 36%
30. Chronic Hepatitis C 36%
31. Ribosomes 36%
32. Down-Regulation 35%
33. Hepacivirus 32%
34. Sustained Virologic Response 31%
35. Colonic Neoplasms 31%
36. Odds Ratio 30%
37. Multicenter Studies 30%
38. Stomach Neoplasms 30%
39. Vascular Endothelial Growth Factor A 30%
40. Population 29%
41. Liver Cirrhosis 27%
42. Growth 27%
43. Mental Health 27%
44. Heterografts 25%
45. Retrospective Studies 25%
46. Cell Line 24%
47. Therapeutics 24%
48. Antigens 22%
49. Neoplasm Metastasis 21%